NEW YORK (GenomeWeb News) – UK molecular diagnostics firm Lumora today announced a licensing deal to develop tests for veterinary diagnostics company Biogal Galed Labs.

The deal provides Israel-based Biogal access to Lumora's technologies, including BART, or Bioluminescent Assay in Real Time, as well as its expertise in test development, reader technologies, and manufacturing, Lumora said. Initially, Lumora will develop a test for leptospirosis, a zoonotic bacterial infection that is transmitted through urine.

Development of other tests is expected to follow.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.